EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling

Molecular Cell

Volumn 60, Issue 2, 2015, Pages 307-318

  Liu, Feng ^a   Hon, Gary C ^a,i   Villa, Genaro R ^a,e   Turner, Kristen M ^a   Ikegami, Shiro ^a   Yang, Huijun ^a   Ye, Zhen ^a   Li, Bin ^a   Kuan, Samantha ^a   Lee, Ah Young ^a   Zanca, Ciro ^a   Wei, Bowen ^e   Lucey, Greg ^e   Jenkins, David ^a   Zhang, Wei ^f   Barr, Cathy L ^g,h   Furnari, Frank B ^a,b   Cloughesy, Timothy F ^e   Yong, William H ^e   Gahman, Timothy C ^a   Shiau, Andrew K ^a   Cavenee, Webster K ^a,c,d   Ren, Bing ^a,b,d   Mischel, Paul S ^a,b,d   more..

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; CASPASE 3; CASPASE 7; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; HISTONE H3; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; TORIN1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXG1; TRANSCRIPTION FACTOR SOX9; TRANSCRIPTOME; UNCLASSIFIED DRUG; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; EGFR PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXG1 PROTEIN, HUMAN; NERVE PROTEIN; SOX9 PROTEIN, HUMAN; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CHROMATIN; CONTROLLED STUDY; DRUG SENSITIZATION; ENHANCER REGION; EPIGENETICS; GENE AMPLIFICATION; GENE MUTATION; GENE ONTOLOGY; GENOME; GENOMICS; GENOTYPE; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE C MYC; TRANSCRIPTION INITIATION; TRANSCRIPTOMICS; TUMOR PROMOTION; ADULT; ANIMAL; BRAIN TUMOR; CANCER TRANSPLANTATION; CELL SURVIVAL; CELL TRANSFORMATION; CHILD; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC EPIGENESIS; GENETICS; METABOLISM; MUTATION; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADULT; ANIMALS; AZEPINES; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CHILD; EPIGENESIS, GENETIC; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; NERVE TISSUE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SOX9 TRANSCRIPTION FACTOR; TRANSCRIPTOME; TRIAZOLES;

EID: 84944896282     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2015.09.002     Document Type: Article

References (51)

1. Akhavan D., Pourzia A.L., Nourian A.A., Williams K.J., Nathanson D., Babic I., Villa G.R., Tanaka K., Nael A., Yang H., et al. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov. 2013, 3:534-547.
2. Babic I., Anderson E.S., Tanaka K., Guo D., Masui K., Li B., Zhu S., Gu Y., Villa G.R., Akhavan D., et al. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab. 2013, 17:1000-1008.
3. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 2011, 11:726-734.
4. Brennan C.W., Verhaak R.G., McKenna A., Campos B., Noushmehr H., Salama S.R., Zheng S., Chakravarty D., Sanborn J.Z., Berman S.H., et al. The somatic genomic landscape of glioblastoma. Cell 2013, 155:462-477. TCGA Research Network.
5. Ciriello G., Miller M.L., Aksoy B.A., Senbabaoglu Y., Schultz N., Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 2013, 45:1127-1133.
6. Cloughesy T.F., Cavenee W.K., Mischel P.S. Glioblastoma: from molecular pathology to targeted treatment. Annu. Rev. Pathol. 2014, 9:1-25.
7. Creyghton M.P., Cheng A.W., Welstead G.G., Kooistra T., Carey B.W., Steine E.J., Hanna J., Lodato M.A., Frampton G.M., Sharp P.A., et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl. Acad. Sci. USA 2010, 107:21931-21936.
8. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
9. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
10. Furnari F.B., Cloughesy T.F., Cavenee W.K., Mischel P.S. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat. Rev. Cancer 2015, 15:302-310.
11. Guo W., Keckesova Z., Donaher J.L., Shibue T., Tischler V., Reinhardt F., Itzkovitz S., Noske A., Zürrer-Härdi U., Bell G., et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 2012, 148:1015-1028.
12. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
13. Heintzman N.D., Stuart R.K., Hon G., Fu Y., Ching C.W., Hawkins R.D., Barrera L.O., Van Calcar S., Qu C., Ching K.A., et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat. Genet. 2007, 39:311-318.
14. Heinz S., Benner C., Spann N., Bertolino E., Lin Y.C., Laslo P., Cheng J.X., Murre C., Singh H., Glass C.K. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 2010, 38:576-589.
15. Herz H.M., Morgan M., Gao X., Jackson J., Rickels R., Swanson S.K., Florens L., Washburn M.P., Eissenberg J.C., Shilatifard A. Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling. Science 2014, 345:1065-1070.
16. Huang H.S., Nagane M., Klingbeil C.K., Lin H., Nishikawa R., Ji X.D., Huang C.M., Gill G.N., Wiley H.S., Cavenee W.K. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J. Biol. Chem. 1997, 272:2927-2935.
17. Kandoth C., McLellan M.D., Vandin F., Ye K., Niu B., Lu C., Xie M., Zhang Q., McMichael J.F., Wyczalkowski M.A., et al. Mutational landscape and significance across 12 major cancer types. Nature 2013, 502:333-339.
18. Lawrence M.S., Stojanov P., Mermel C.H., Robinson J.T., Garraway L.A., Golub T.R., Meyerson M., Gabriel S.B., Lander E.S., Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014, 505:495-501.
19. Lee T.I., Young R.A. Transcriptional regulation and its misregulation in disease. Cell 2013, 152:1237-1251.
20. Lewis P.W., Müller M.M., Koletsky M.S., Cordero F., Lin S., Banaszynski L.A., Garcia B.A., Muir T.W., Becher O.J., Allis C.D. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013, 340:857-861.
21. Lin C.Y., Lovén J., Rahl P.B., Paranal R.M., Burge C.B., Bradner J.E., Lee T.I., Young R.A. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012, 151:56-67.
22. Lovén J., Hoke H.A., Lin C.Y., Lau A., Orlando D.A., Vakoc C.R., Bradner J.E., Lee T.I., Young R.A. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153:320-334.
23. Mansour M.R., Abraham B.J., Anders L., Berezovskaya A., Gutierrez A., Durbin A.D., Etchin J., Lawton L., Sallan S.E., Silverman L.B., et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 2014, 346:1373-1377.
24. Masui K., Tanaka K., Akhavan D., Babic I., Gini B., Matsutani T., Iwanami A., Liu F., Villa G.R., Gu Y., et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 2013, 18:726-739.
25. Mermel C.H., Schumacher S.E., Hill B., Meyerson M.L., Beroukhim R., Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011, 12:R41.
26. Nathanson D.A., Gini B., Mottahedeh J., Visnyei K., Koga T., Gomez G., Eskin A., Hwang K., Wang J., Masui K., et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 2014, 343:72-76.
27. Nie Z., Hu G., Wei G., Cui K., Yamane A., Resch W., Wang R., Green D.R., Tessarollo L., Casellas R., et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012, 151:68-79.
28. Ozawa T., James C.D. Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging. J. Vis. Exp. 2010, (41):1986.
29. Parker B.C., Annala M.J., Cogdell D.E., Granberg K.J., Sun Y., Ji P., Li X., Gumin J., Zheng H., Hu L., et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J. Clin. Invest. 2013, 123:855-865.
30. Patel A.P., Tirosh I., Trombetta J.J., Shalek A.K., Gillespie S.M., Wakimoto H., Cahill D.P., Nahed B.V., Curry W.T., Martuza R.L., et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014, 344:1396-1401.
31. Rada-Iglesias A., Bajpai R., Swigut T., Brugmann S.A., Flynn R.A., Wysocka J. A unique chromatin signature uncovers early developmental enhancers in humans. Nature 2011, 470:279-283.
32. Rani S.B., Rathod S.S., Karthik S., Kaur N., Muzumdar D., Shiras A.S. MiR-145 functions as a tumor-suppressive RNA by targeting Sox9 and adducin 3 in human glioma cells. Neuro-oncol. 2013, 15:1302-1316.
33. Rheinbay E., Suvà M.L., Gillespie S.M., Wakimoto H., Patel A.P., Shahid M., Oksuz O., Rabkin S.D., Martuza R.L., Rivera M.N., et al. An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep. 2013, 3:1567-1579.
34. Rivera C.M., Ren B. Mapping human epigenomes. Cell 2013, 155:39-55.
35. Robinson M.D., McCarthy D.J., Smyth G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010, 26:139-140.
36. Sarkaria J.N., Yang L., Grogan P.T., Kitange G.J., Carlson B.L., Schroeder M.A., Galanis E., Giannini C., Wu W., Dinca E.B., James C.D. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol. Cancer Ther. 2007, 6:1167-1174.
37. Seoane J., Le H.V., Shen L., Anderson S.A., Massagué J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 2004, 117:211-223.
38. Shen H., Laird P.W. Interplay between the cancer genome and epigenome. Cell 2013, 153:38-55.
39. Shi J., Vakoc C.R. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell 2014, 54:728-736.
40. Singh D., Chan J.M., Zoppoli P., Niola F., Sullivan R., Castano A., Liu E.M., Reichel J., Porrati P., Pellegatta S., et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012, 337:1231-1235.
41. Stratton M.R. Exploring the genomes of cancer cells: progress and promise. Science 2011, 331:1553-1558.
42. Sturm D., Bender S., Jones D.T., Lichter P., Grill J., Becher O., Hawkins C., Majewski J., Jones C., Costello J.F., et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat. Rev. Cancer 2014, 14:92-107.
43. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
44. Suvà M.L., Riggi N., Bernstein B.E. Epigenetic reprogramming in cancer. Science 2013, 339:1567-1570.
45. Suvà M.L., Rheinbay E., Gillespie S.M., Patel A.P., Wakimoto H., Rabkin S.D., Riggi N., Chi A.S., Cahill D.P., Nahed B.V., et al. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell 2014, 157:580-594.
46. Swartling F.J., Savov V., Persson A.I., Chen J., Hackett C.S., Northcott P.A., Grimmer M.R., Lau J., Chesler L., Perry A., et al. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell 2012, 21:601-613.
47. Verginelli F., Perin A., Dali R., Fung K.H., Lo R., Longatti P., Guiot M.C., Del Maestro R.F., Rossi S., di Porzio U., et al. Transcription factors FOXG1 and Groucho/TLE promote glioblastoma growth. Nat. Commun. 2013, 4:2956.
48. Vivanco I., Robins H.I., Rohle D., Campos C., Grommes C., Nghiemphu P.L., Kubek S., Oldrini B., Chheda M.G., Yannuzzi N., et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012, 2:458-471.
49. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
50. Wang M.Y., Lu K.V., Zhu S., Dia E.Q., Vivanco I., Shackleford G.M., Cavenee W.K., Mellinghoff I.K., Cloughesy T.F., Sawyers C.L., Mischel P.S. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 2006, 66:7864-7869.
51. Wang L., He S., Yuan J., Mao X., Cao Y., Zong J., Tu Y., Zhang Y. Oncogenic role of SOX9 expression in human malignant glioma. Med. Oncol. 2012, 29:3484-3490.